386 results
The EBM Focus team at DynaMed® discusses a large cohort study evaluating risk of myocarditis after COVID vaccination.
Mixed evidence for procalcitonin to identify bacterial infections contributes to the confusion over whether it is useful. Read about a new pragmatic trial evaluating procalcitonin with or without point-of-care ultrasound for suspected pneumonia.
Will Estimating GFR Without Adjusting for Race Help to Reduce Racial Bias in Chronic Kidney Disease?
Estimating glomerular filtration rate (GFR) includes adjusting for race, leading to disparities in care of Black patients with kidney disease. The team at DynaMed® examines this racial bias.
How does a revised newborn pulse-ox screening algorithm for critical congenital heart defects (CCHD) compare to standard screening? The EBM Focus team at DynaMed® investigates.
Read about a large, real-time public health study evaluating effectiveness of a third (booster) dose of Pfizer COVID-19 vaccine from the EBM Focus team at DynaMed®.
The EBM Focus team at DynaMed® picks its favorite articles of 2021. Find the top five articles in this 2021 Year in Review.
The most recent COVID variant, Omicron, was identified in November 2021 and rapidly spread across the globe. Here are answers to the top five questions about the Omicron variant.
Nonfatal myocardial infarction (MI) is a commonly used surrogate outcome in trials of interventions for acute coronary syndromes. The EBM Focus team evaluates whether it is a reasonable endpoint.
Nearly all patients with MEN1 develop tumors, so screening is an important aspect of managing disease progression. Find tips for developing a balanced and thoughtful approach to screening in the latest blog article from the editors at DynaMed.
In part two of this series on statins for primary prevention of cardiovascular disease, we investigate the Individual Patient Data Meta-Analysis (IPDMAs) from the Cholesterol Treatment Trialists (CTT), including how these data fit into “the big picture”.